Recent Articles from Benzinga
Benzinga, founded in 2010 by Jason Raznick and headquartered in Detroit, Michigan, is a dynamic financial media and technology company dedicated to empowering individual investors with timely, actionable insights. Initially launched from Raznick’s basement with a modest $10,000 investment, the company has grown into a trusted resource, attracting approximately 25 million monthly readers through its innovative blend of real-time financial news, market analysis, and trading tools.
Website: https://www.benzinga.com
Shares of Archer Aviation Inc. (NASDAQ: ACHR) are rising Monday after the company announced a major partnership with an airline.
Via Benzinga · October 20, 2025
Gold's Path To $10K Please click here for an enlarged chart of SPDR Gold Trust (NYSE:GLD).
Via Benzinga · October 20, 2025
Via Benzinga · October 20, 2025
Bitcoin (CRYPTO: BTC) and Ethereum (CRYPTO: ETH) are up on Monday after the U.K.'s Financial Conduct Authority lifted its four-year retail ban on crypto exchange-traded notes, allowing 21Shares, Bitwise
Via Benzinga · October 20, 2025
Shares of BitMine Immersion Technologies, Inc. (NASDAQ:BMNR) are trading higher. The company on Monday provided an update on its crypto holdings.
Via Benzinga · October 20, 2025
AppLovin shares are trading lower on Monday. Short Seller Fuzzy Panda highlighted recent reports regarding potential investigations by multiple state attorneys general.
Via Benzinga · October 20, 2025
Bitfarms Ltd.
Via Benzinga · October 20, 2025
DoorDash (DASH) may report high Q3 results and increase estimates due to strong tracking data and acquisition of Deliveroo. Analysts reiterate Buy rating and target price of $315.
Via Benzinga · October 20, 2025
Microsoft (MSFT) sees strong demand for security services in Azure, leading to higher capital expenditure and upbeat earnings forecasts.
Via Benzinga · October 20, 2025
Via Benzinga · October 20, 2025
Snowflake (SNOW) gaining momentum as it expands its AI Data Cloud, capturing a growing share of the AI market. Wedbush raises price target to $270.
Via Benzinga · October 20, 2025
Defiance ETFs has launched the 2X Long LMND ETF (LMNX), giving traders double daily exposure to Lemonade Inc. for short-term bullish plays.
Via Benzinga · October 20, 2025
Via Benzinga · October 20, 2025
Via Benzinga · October 20, 2025
Via Benzinga · October 20, 2025
Via Benzinga · October 20, 2025
Via Benzinga · October 20, 2025
Via Benzinga · October 20, 2025
Via Benzinga · October 20, 2025
Via Benzinga · October 20, 2025
Via Benzinga · October 20, 2025
Via Benzinga · October 20, 2025
Via Benzinga · October 20, 2025
Via Benzinga · October 20, 2025
Via Benzinga · October 20, 2025
Via Benzinga · October 20, 2025
Nvidia's exit from China may seem like a market loss, but it actually shows the company's focus on high-margin, AI-driven opportunities.
Via Benzinga · October 20, 2025
Jamie Dimon warns of hidden credit risks as stress builds in regional banks and private equity. Analysts turn to long-duration Treasuries and small-cap hedges as potential portfolio protection.
Via Benzinga · October 20, 2025
Via Benzinga · October 20, 2025
Exelixis stock dips after Phase 3 data show modest survival gains from zanzalintinib and Tecentriq combo in colorectal cancer patients.
Via Benzinga · October 20, 2025
Via Benzinga · October 20, 2025
BREM is an actively managed fund offering flexible exposure to sovereign and corporate debt in developing economies.
Via Benzinga · October 20, 2025
Morningstar analyst Dan Sotiroff warns that the leveraged ETF boom, including new 5X filings, reflects speculative excess rather than genuine investing.
Via Benzinga · October 20, 2025
XBP Global Holdings, Inc. (NASDAQ: XBP) partners with NYC Department of Finance to improve parking ticket payments.
Via Benzinga · October 20, 2025
Via Benzinga · October 20, 2025
Norwegian Cruise Line Holdings signs a long-term renewable fuel supply deal with Repsol at the Port of Barcelona.
Via Benzinga · October 20, 2025
Via Benzinga · October 20, 2025
Lucid is blending its innovation with sports, fashion, and entertainment, starting with Timothée Chalamet earlier this year.
Via Benzinga · October 20, 2025
Via Benzinga · October 20, 2025
Via Benzinga · October 20, 2025
Summit Therapeutics shares Phase 3 data showing ivonescimab cut cancer progression risk by 40% and plans BLA submission in late 2025.
Via Benzinga · October 20, 2025
Via Benzinga · October 20, 2025
Via Benzinga · October 20, 2025